Fluconazole Dosing, Side Effects & Interactions: Expert Guide
Authoritative facts about fluconazole including its uses in dermatology, dosing for skin infections, side effects and drug interactions.
Authoritative facts about fluconazole including its uses in dermatology, dosing for skin infections, side effects and drug interactions.
What is fluconazole?
Fluconazole is a member of the triazole antifungal family of medicines. It was patented in 1981 and came into medical use in 1988. Fluconazole is a highly selective inhibitor of fungal cytochrome P450 dependent enzyme lanosterol 14-α-demethylase. This enzyme functions to convert lanosterol to ergosterol. The subsequent loss of normal sterols correlates with the accumulation of 14-α-methyl sterols in fungi and may be responsible for the fungistatic activity of fluconazole.
Mammalian cell demethylation is much less sensitive to fluconazole inhibition. Fluconazole has been demonstrated to show fungistatic activity against the majority of strains of the following microorganisms: Candida albicans, Candida glabrata (many strains are intermediately susceptible), Candida parapsisosis, Candida tropicalis, Cryptococcus neoformans.
Fluconazole works by slowing the growth of fungi that cause infection. It interacts with 14-demethylase, a cytochrome P-450 enzyme responsible for catalyzing the conversion of lanosterol to ergosterol. As ergosterol forms a critical part of the fungal cell membrane, fluconazole inhibits the synthesis of ergosterol to increase cellular permeability.
Who gets fungal infections treated with fluconazole?
Fluconazole is used to treat serious fungal or yeast infections, including vaginal candidiasis, oropharyngeal candidiasis (thrush), esophageal candidiasis, other candida infections (including urinary tract infections, peritonitis, and infections that may occur in different parts of the body), or fungal (cryptococcal) meningitis.
In dermatology, fluconazole treats superficial fungal infections of the skin such as those caused by dermatophytes (tinea) and yeasts (candida). Patients with extensive or recalcitrant infections, or those unable to use topical antifungals, benefit from systemic therapy like fluconazole. Immunocompromised individuals, including those with HIV, cancer patients undergoing chemotherapy, or post-transplant patients, are particularly susceptible to fungal infections requiring fluconazole prophylaxis or treatment.
What causes fungal infections treated with fluconazole?
Fungal infections treated with fluconazole are caused by pathogenic yeasts and dermatophytes. Common pathogens include:
- Candida species: C. albicans (most common), C. glabrata, C. parapsilosis, C. tropicalis, C. krusei (often resistant)
- Cryptococcus neoformans: causes meningitis in immunocompromised patients
- Dermatophytes: Trichophyton, Microsporum, Epidermophyton species causing tinea infections
- Malassezia species: pityriasis versicolor
- Aspergillus spp. and other moulds (limited activity)
Fluconazole is active against most Candida species but resistance is emerging, particularly in C. glabrata and C. krusei. Susceptibility testing is recommended for serious infections.
What are the clinical features of fluconazole-treated fungal infections?
Skin infections treated with fluconazole present as:
- Tinea corporis/cruris/pedis: Annular erythematous scaly plaques with central clearing and raised border
- Cutaneous candidiasis: Moist erythematous plaques in flexures, satellite pustules
- Pityriasis versicolor: Hypo/hyperpigmented fine scaling macules on trunk
- Onychomycosis: Dystrophic nails due to dermatophytes or candida
On examination, microscopy with KOH confirms hyphae or spores. Culture identifies the species and antifungal susceptibility.
How is the diagnosis of fungal infection made when using fluconazole?
Diagnosis before prescribing fluconazole requires:
- Clinical assessment: Characteristic morphology and distribution
- Microscopy: 10–30% KOH preparation showing fungal elements
- Culture: Sabouraud agar for identification and susceptibility
- Wood lamp: For Microsporum infections (rare)
- Histopathology: PAS stain for deeper infections
Susceptibility testing guides therapy in resistant or systemic cases.
What is the basic management of fungal infections treated with fluconazole?
Specific investigation for fluconazole therapy
- Confirm diagnosis with microscopy/culture before systemic therapy
- Liver function tests (LFTs) baseline for courses >2 weeks
- ECG if on interacting drugs (e.g., QT prolonging agents)
Management algorithm for fluconazole
- Uncomplicated tinea/candida: Topical antifungal first-line
- Extensive/recalcitrant: Fluconazole 50–150mg weekly for 2–6 weeks
- Nail infections: 150–450mg weekly for 3–12 months
- Systemic/prophylaxis: Per guidelines, monitor LFTs
Fluconazole dosing in dermatology
| Condition | Dose | Duration |
|---|---|---|
| Tinea corporis/cruris/pedis | 150–200mg weekly | 2–4 weeks |
| Cutaneous candidiasis | 50–100mg daily | 2–4 weeks |
| Pityriasis versicolor | 300–400mg weekly or 50mg daily | 2 weeks |
| Onychomycosis | 150–450mg weekly | 3–12 months |
| Vaginal candidiasis | 150mg single dose | 1 day |
Author: Adjusted for dermatology from general indications. Caution: Pregnancy category D; avoid in first trimester.
Side effects of fluconazole
Fluconazole is generally well-tolerated. Common side effects (>1%):
- Gastrointestinal: Nausea (3.7%), abdominal pain (2.7%), diarrhoea (1.5%), vomiting (1.7%)
- Headache (1.9%)
- Rash (1.8%)
Serious (<1%):
- Hepatotoxicity (ALT elevation; rare fulminant hepatitis)
- QT prolongation, torsades de pointes
- Stevens-Johnson syndrome/toxic epidermal necrolysis (rare)
- Anaphylaxis
Monitor LFTs in prolonged therapy. Discontinue if ALT >3x ULN.
Drug interactions with fluconazole
Fluconazole inhibits CYP3A4/CYP2C9 moderately, causing interactions:
| Drug class | Examples | Effect |
|---|---|---|
| Statins | Simvastatin, atorvastatin | ↑ levels; rhabdomyolysis risk |
| Warfarin | – | ↑ INR |
| Benzodiazepines | Midazolam | ↑ sedation |
| QT drugs | Amiodarone, erythromycin | Arrhythmia risk |
| Sulphonylureas | Gliclazide | ↑ hypoglycaemia |
| Protease inhibitors | — | ↑ levels |
Check interactions before prescribing. Rifampicin decreases fluconazole levels.
Alternative treatments for fluconazole-resistant infections
- Topical: Terbinafine, clotrimazole for mild cases
- Oral itraconazole: Broader dermatophyte activity
- Terbinafine: Preferred for dermatophyte onychomycosis
- Echinocandins (caspofungin): For invasive candida
- Amphotericin B: For cryptococcal meningitis
Susceptibility testing essential for failures.
Prevention of fungal infections when using fluconazole
- Avoid occlusive clothing in flexures
- Dry skin thoroughly post-bathing
- Prophylaxis in high-risk patients (e.g., 200mg weekly HIV)
- Complete full course to prevent resistance
Guidelines for using fluconazole
- First-line for vaginal candida, pityriasis versicolor
- Second-line for tinea after topical failure
- Avoid in pregnancy (teratogenic)
- Not for moulds (Aspergillus, mucor)
- Monitor LFTs >2 weeks; pregnancy test females
Emerging issues with fluconazole
Increasing resistance in non-albicans Candida (C. glabrata, krusei). Stewardship recommends culture-guided therapy.
Frequently asked questions about fluconazole
Q: Is fluconazole safe in pregnancy?
A: No. Category D; associated with birth defects. Avoid unless life-threatening maternal infection.
Q: How long until fluconazole works for tinea?
A: Improvement in 1–2 weeks; complete full course to prevent relapse.
Q: Can fluconazole treat nail fungus?
A: Yes, 150–450mg weekly for 3–12 months. Terbinafine often preferred.
Q: Does fluconazole interact with the pill?
A: Minimal effect but use backup contraception during treatment + 2 days after.
Q: When to monitor liver function on fluconazole?
A: Baseline and 2-weekly for intermittent dosing >2 months or daily >1 week.
References
- Fluconazole (oral route) – Mayo Clinic — Mayo Foundation for Medical Education and Research. 2023-10-01. https://www.mayoclinic.org/drugs-supplements/fluconazole-oral-route/description/drg-20071428
- Fluconazole: MedlinePlus Drug Information — U.S. National Library of Medicine. 2024-05-15. https://medlineplus.gov/druginfo/meds/a690002.html
- Fluconazole – StatPearls – NCBI Bookshelf — National Center for Biotechnology Information. 2023-11-20. https://www.ncbi.nlm.nih.gov/books/NBK537158/
- Fluconazole: Uses, Interactions, Mechanism of Action | DrugBank — DrugBank Online. 2024-01-10. https://go.drugbank.com/drugs/DB00196
- Diflucan (fluconazole) tablets label — U.S. Food and Drug Administration. 2011-10-27. https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019949s051lbl.pdf
- Fluconazole (Diflucan) – iapac.org — International Association of Providers of AIDS Care. 2023-08-01. https://www.iapac.org/fact-sheet/fluconazole-diflucan/
Similar Articles
Read full bio of medha deb
